Linvoseltamab - CISMeF

Preferred Label : Linvoseltamab;

NCIt synonyms : BCMA x CD3 Bispecific Antibody REGN5458; Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5458; Anti-BCMA/CD3 Bispecific Antibody REGN5458;

NCIt definition : A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.;

UNII : M3CPC50MZS;

CAS number : 2408319-25-3;

Drug name : Lynozyfic;

Molecule name : REGN 5458; REGN-5458;

NCI Metathesaurus CUI : CL938057;

Details

Origin ID

C158504;

UMLS CUI

C5667182;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tumor Necrosis Factor Receptor Superfamily Member 17 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients